Byotrol PLC operates within the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Byotrol PLC with three other
pharmaceutical manufacturers in Europe:
sales of £498,000.00 [US$663,116.88 ]
Summit Therapeutics PLC
(£2.30 million [US$3.07 million]
of which 100%
was Drug Discovery), and
Collagen Solutions PLC
(£3.95 million [US$5.25 million]
During the year ended March of 2017, sales at
Byotrol PLC were £3.13 million (US$4.16 million).
increase of 18.1%
versus 2016, when the company's sales were £2.65 million.
Despite this increase, sales are still
below the level achieved in 2015, when Byotrol PLC
reported sales of £3.25 million.
Sales of Consumer saw an increase
that was more than double the company's growth rate: sales were up
118.4% in 2017, from
£527,521.00 to £1.15 million.
Not all segments of Byotrol PLC experienced an increase in sales in 2017:
sales of Professional fell 17.5% to £1.18 million.